This is an informal report intended primarily for internal or limited external distribution. The opinions and conclusions stated are those of the author and may or may not be those of the Laboratory.
T. Freeman
In 1997 we first postulated the existence of a special human population that had had their skeletons inadvertently isotopically adulterated in the past. We theorized that the population, and the necessary LLNL accelerator mass spectrometer (AMS) measurement technology, would prove a significant resource in the fight to combat osteoporosis. This LDRD project was to establish such. The project was significantly successful in its initial year, but was not renewed for another and the research is now ended at LLNL.
Osteoporosis is a major public health problem. In the United States alone, there are over a million osteoporotic fractures a year; these have an attendant annual financial cost of more than $10 billion. Consequently, there are considerable efforts to develop therapies and a great need for better diagnostic tools.
Osteoporosis is a disease characterized by reduced bone mineral density (BMD). Skeletal calcium deposition and resorption are usually closely coupled, but prolonged slight net imbalances ultimately deplete the skeleton. Many current therapies are directed at redressing this imbalance by partially blocking bone resorption. The evaluation of these, and of other therapies more generally, requires good measurements of skeletal calcium loss. However, the current x-ray techniques are insensitive to changes and the preferred alternative techniques of using urine/serum proxy biomarkers only poorly predict an individual's BMD. The goal of this project was to establish a potentially more powerful method for monitoring bone degradation: the direct measurement of resorbed and excreted skeletal calcium. This promises better, faster, and less-expensive development of therapies.
Recent work has demonstrated the necessary labeling of the human skeleton with an isotope novel to calcium kinetics research, 41 Ca, coupled with ultrasensitive AMS detection in processed urine of the minute amounts of the tracer resorbed and excreted in any day. Although a single tracer administration can usefully label the skeleton for life, a significant outstanding issue was that it might take years of normal skeletal remodeling before the 41 Ca signal of resorption would usefully reflect skeletal resorption. However, we realized that historical experimental subjects had received previously unrecognized 41 Ca tracer as an impurity in other radiotracers in unrelated experiments performed by other researchers even many years in advance. Thus, it transpires that there exist thousands of one-time experimental subjects who, by virtue of having been accidentally labeled sufficiently long ago, now have skeletons with thoroughly equilibrated tracer. If even a small fraction of this unique population were available for enrollment into contemporary protocols, then these subjects might prove the ideal population for evaluation of osteoporosis therapies. At the very least, measurements of existing historical samples would provide unique fundamental bone kinetics data, as for the first time the long-term evolution of a calcium bolus can be monitored, and in a population sufficient for epidemiology at that.
We proposed a three-year program to (1) confirm the magnitude and extent of historical 41 Ca dosing, (2) exactly characterize the long-term 41 Ca signal by comparing it with conventional measurements of skeletal health, and (3) demonstrate the utility of the historically labeled population in evaluating an actual potential therapy for osteoporosis. However, rather than investigate historical records to learn the identity of those inadvertently dosed, find them, and if possible enroll them into a new protocol, this project was to be particularly efficient by making use of a multiyear archive of samples from original, inadvertent 41 Ca-dosing experiments at Creighton University in Omaha, Nebraska. Because the subjects had been dosed i n conventional studies of calcium kinetics, much important correlating historical data would also be available for comparison. Measurements of contemporary urine samples specifically provided for this project by selected identified subjects would follow.
To confirm widespread 41 Ca dosing, during FY98 we investigated the neutron irradiation genesis and administration of the 41 Ca impurity in the original radiotracers. This involved researching the historical use of the impure short-lived 45 Ca and 47 Ca radiotracers in bioavailability studies and investigations of metabolic bone diseases in general, reconstructing the historical Creighton University experiments from records in particular, and the analysis of historical radiotracer dosing solutions from the Creighton archive. The necessary new protocols for preparing the solutions were developed in collaboration with University of California at Davis scientists also. The 41 Ca impurities in 47 Ca radiotracer is graphed 
